Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Schmidt, R; Neff, F; Lampl, C; Benke, T; Anditsch, M; Bancher, C; Dal-Bianco, P; Reisecker, F; Marksteiner, J; Rainer, M; Kapeller, P; Dodel, R.
Therapy of Alzheimer's disease: current status and future development
Neuropsychiatr. 2008; 22(3):153-171
Web of Science
PubMed
- Leading authors Med Uni Graz
- Schmidt Reinhold
- Co-authors Med Uni Graz
- Kapeller Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- Cholinesterase inhibitors and memantine can slow the course of Alzheimer's disease. In Austria the frequency of treatment is in the upper third among countries of the EU. Yet, the majority of Alzheimer patients does not receive adequate medication. Compliance to treatment is low. Studies on cholinesterase inhibitors show that only one third and one fifth of patients adhere to medication after 3 months and 12 months, respectively. Causes for low compliance are only partly patient-related, many factors are system-inherent. Knowledge of these factors is a pre-requisite for the treating physician to improve current unfavourable situation. Present treatment strategies are symptomatic, causal disease-modifying therapies are urgently needed. Research activity in the field is high and dominated by the amyloid hypothesis. We here review the basis and recent studies on secretase-inhibitors, immunization, aggregation of Abeta, statins and PPARgamma-agonists. Research towards strategies against tau-pathology is less dominant and focuses on inhibition of kinases and increase of activity of phosphatases. Causal therapies would have great effects on a population basis even if efficacy is only moderate. A disease-modifying therapy which delays the onset of Alzheimer disease by 5 years, will probably reduce the number of patients by nearly 50% during the next 50 years.
- Find related publications in this database (using NLM MeSH Indexing)
- Alzheimer Disease - diagnosis
- Alzheimer Vaccines - therapeutic use
- Amyloid Precursor Protein Secretases - antagonists and inhibitors
- Amyloid beta-Protein - immunology
- Animals -
- Brain - drug effects
- Cholinesterase Inhibitors - adverse effects
- Drug Interactions -
- Drug Utilization - statistics and numerical data
- Drugs, Investigational - adverse effects
- Humans -
- Immunotherapy -
- Memantine - adverse effects
- Neurofibrillary Tangles - drug effects
- Nootropic Agents - adverse effects
- Patient Compliance - statistics and numerical data
- Senile Plaques - drug effects
- Find related publications in this database (Keywords)
- Alzheimer dementia
- cholinesterase inhibitors
- drug interactions
- once daily use
- compliance
- therapeutic strategies